Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.

Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society1 Apr 1999Cited by 13 (Europe PMC)

PMID10373343DOI10.1054/ghir.1999.9998PepBankPUB-10373343

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In adult female rats, ipamorelin dose-dependently increased the longitudinal growth rate of the tibia compared with vehicle (P<0.0001).
In plain wordsIn rats, ipamorelin increased the growth rate of the shin bone in a dose-dependent way compared with vehicle.
Peptide
Ipamorelin
Outcome
IncreaseLongitudinal bone growth rate
Study
ratn: not reported in source
Adult female rats
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
18, 90 and 450 microg/day · subcutaneous · 15 daysAs given in this study (rat).
Measurements
Longitudinal growth rate
42 microm/day
vehicle
Longitudinal growth rate
44 microm/day
treatment group 1
Longitudinal growth rate
50 microm/day
treatment group 2
Longitudinal growth rate
52 microm/day
treatment group 3
Source sentences
Summary
Ipamorelin dose-dependently increased LGR from 42 microm/day in the vehicle group to 44, 50, and 52 microm/day in the treatment groups (P<0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
With the objective of investigating the effects on longitudinal bone growth rate (LGR), body weight (BW), and GH release, ipamorelin in different doses (0, 18, 90 and 450 microg/day) was injected s.c. three times daily for 15 days to adult female rats.
Report a problemFND-1037334301
02AnimalAnimal study (in vivo)Efficacy outcome
In adult female rats, ipamorelin had a pronounced and dose-dependent effect on body weight gain.
In plain wordsIn rats, ipamorelin increased weight gain in a dose-dependent way.
Peptide
Ipamorelin
Outcome
IncreaseBody weight gain
Study
ratn: not reported in source
Adult female rats
Comparator
Vehicle
Outcome group
Body weight · Metabolic and weight
Studied dose
18, 90 and 450 microg/day · subcutaneous · 15 daysAs given in this study (rat).
Source sentences
Summary
There was also a pronounced and dose-dependent effect on BW gain.
1 context sentence(design, population, supporting numbers)
Summary · context
With the objective of investigating the effects on longitudinal bone growth rate (LGR), body weight (BW), and GH release, ipamorelin in different doses (0, 18, 90 and 450 microg/day) was injected s.c. three times daily for 15 days to adult female rats.
Report a problemFND-1037334302
03AnimalAnimal study (in vivo)Efficacy outcome
In adult female rats, ipamorelin treatment did not affect total IGF-I levels.
In plain wordsIn rats, ipamorelin did not change total IGF-I levels.
Peptide
Ipamorelin
Outcome
No significant changeTotal IGF-I levels
Study
ratn: not reported in source
Adult female rats
Comparator
Vehicle
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
18, 90 and 450 microg/day · subcutaneous · 15 daysAs given in this study (rat).
Source sentences
Summary
The treatment did not affect total IGF-I levels
1 context sentence(design, population, supporting numbers)
Summary · context
With the objective of investigating the effects on longitudinal bone growth rate (LGR), body weight (BW), and GH release, ipamorelin in different doses (0, 18, 90 and 450 microg/day) was injected s.c. three times daily for 15 days to adult female rats.
Report a problemFND-1037334303
04AnimalAnimal study (in vivo)Efficacy outcome
In adult female rats, ipamorelin treatment did not affect IGF binding proteins.
In plain wordsIn rats, ipamorelin did not change IGF binding proteins.
Peptide
Ipamorelin
Outcome
No significant changeIGF binding proteins
Study
ratn: not reported in source
Adult female rats
Comparator
Vehicle
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
18, 90 and 450 microg/day · subcutaneous · 15 daysAs given in this study (rat).
Source sentences
Summary
The treatment did not affect total IGF-I levels, IGFBPs
1 context sentence(design, population, supporting numbers)
Summary · context
With the objective of investigating the effects on longitudinal bone growth rate (LGR), body weight (BW), and GH release, ipamorelin in different doses (0, 18, 90 and 450 microg/day) was injected s.c. three times daily for 15 days to adult female rats.
Report a problemFND-1037334304
05AnimalAnimal study (in vivo)Efficacy outcome
In adult female rats, ipamorelin treatment did not affect serum markers of bone formation and resorption.
In plain wordsIn rats, ipamorelin did not change blood markers of bone formation or bone breakdown.
Peptide
Ipamorelin
Outcome
No significant changeSerum markers of bone formation and resorption
Study
ratn: not reported in source
Adult female rats
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
18, 90 and 450 microg/day · subcutaneous · 15 daysAs given in this study (rat).
Source sentences
Summary
or serum markers of bone formation and resorption.
1 context sentence(design, population, supporting numbers)
Summary · context
With the objective of investigating the effects on longitudinal bone growth rate (LGR), body weight (BW), and GH release, ipamorelin in different doses (0, 18, 90 and 450 microg/day) was injected s.c. three times daily for 15 days to adult female rats.
Report a problemFND-1037334305
06AnimalAnimal study (in vivo)Efficacy outcome
In adult female rats, the number of tartrate-resistant acid phosphatase-positive multinuclear cells in the tibial metaphysis did not change significantly with ipamorelin.
In plain wordsIn rats, ipamorelin did not significantly change the number of bone-resorbing cells in the shin bone.
Peptide
Ipamorelin
Outcome
No significant changeTRAP-positive multinuclear cells in tibial metaphysis
Study
ratn: not reported in source
Adult female rats
Comparator
Vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
18, 90 and 450 microg/day · subcutaneous · 15 daysAs given in this study (rat).
Source sentences
Summary
The number of tartrate-resistant acid phosphatase-positive multinuclear cells in the metaphysis of the tibia did not change significantly with treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
With the objective of investigating the effects on longitudinal bone growth rate (LGR), body weight (BW), and GH release, ipamorelin in different doses (0, 18, 90 and 450 microg/day) was injected s.c. three times daily for 15 days to adult female rats.
Report a problemFND-1037334306
07AnimalAnimal study (in vivo)Efficacy outcome
In adult female rats treated with ipamorelin, the plasma GH response to a provocative i.v. dose of ipamorelin was marginally reduced (P<0.03).
In plain wordsIn rats, after 15 days of ipamorelin, the growth hormone response to a new ipamorelin dose was slightly smaller.
Peptide
Ipamorelin
Outcome
DecreasePlasma GH response to provocative ipamorelin dose
Study
ratn: not reported in source
Adult female rats
Comparator
Vehicle
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
18, 90 and 450 microg/day · subcutaneous · 15 daysAs given in this study (rat).
Source sentences
Summary
The responsiveness of the pituitary to a provocative i.v. dose of ipamorelin or GHRH showed that the plasma GH response was marginally reduced (P<0.03) after ipamorelin
1 context sentence(design, population, supporting numbers)
Summary · context
With the objective of investigating the effects on longitudinal bone growth rate (LGR), body weight (BW), and GH release, ipamorelin in different doses (0, 18, 90 and 450 microg/day) was injected s.c. three times daily for 15 days to adult female rats.
Report a problemFND-1037334307
08AnimalAnimal study (in vivo)Efficacy outcome
In adult female rats treated with ipamorelin, the plasma GH response to a provocative i.v. dose of GHRH was unchanged.
In plain wordsIn rats, after 15 days of ipamorelin, the growth hormone response to GHRH did not change.
Peptide
Ipamorelin
Outcome
No significant changePlasma GH response to GHRH
Study
ratn: not reported in source
Adult female rats
Comparator
Vehicle
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
18, 90 and 450 microg/day · subcutaneous · 15 daysAs given in this study (rat).
Source sentences
Summary
The responsiveness of the pituitary to a provocative i.v. dose of ipamorelin or GHRH
2 context sentences(design, population, supporting numbers)
Summary · context
but unchanged after GHRH.
Summary · context
With the objective of investigating the effects on longitudinal bone growth rate (LGR), body weight (BW), and GH release, ipamorelin in different doses (0, 18, 90 and 450 microg/day) was injected s.c. three times daily for 15 days to adult female rats.
Report a problemFND-1037334308
09AnimalAnimal study (in vivo)Efficacy outcome
In adult female rats, pituitary GH content was unchanged by ipamorelin treatment.
In plain wordsIn rats, ipamorelin treatment did not change the growth hormone content of the pituitary gland.
Peptide
Ipamorelin
Outcome
No significant changePituitary GH content
Study
ratn: not reported in source
Adult female rats
Comparator
Vehicle
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
18, 90 and 450 microg/day · subcutaneous · 15 daysAs given in this study (rat).
Source sentences
Summary
The pituitary GH content was unchanged by ipamorelin treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
With the objective of investigating the effects on longitudinal bone growth rate (LGR), body weight (BW), and GH release, ipamorelin in different doses (0, 18, 90 and 450 microg/day) was injected s.c. three times daily for 15 days to adult female rats.
Report a problemFND-1037334309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.